Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study

Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy.